Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Publikováno v:
Cancers, Vol 16, Iss 3, p 501 (2024)
Immune checkpoint inhibitor (ICI) therapy improves outcomes in several cancers. Unfortunately, many patients experience grade 3–4 treatment-related adverse events, including gastrointestinal (GI) toxicities which are common. These GI immune-related
Externí odkaz:
https://doaj.org/article/d33b64371b5b45c7aca256c09a1afb1d
Autor:
Jennifer E. Yeh, MD, PhD, Marilyn T. Wan, MBChB, MPH, Allireza Alloo, MD, Nageatte Ibrahim, MD, Patrick A. Ott, MD, PhD, Elizabeth I. Buchbinder, MD, Jennifer Y. Lin, MD
Publikováno v:
JAAD Case Reports, Vol 27, Iss , Pp 162-166 (2022)
Externí odkaz:
https://doaj.org/article/61a899a064ef46b1bfe0e0024ac4aba0
Autor:
Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patrick A. Ott, Rizwan Haq, Benjamin Izar, Anita Giobbie‐Hurder, F. Stephen Hodi
Publikováno v:
Cancer Medicine, Vol 10, Iss 8, Pp 2627-2635 (2021)
Abstract Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint blockade (ICB). However, response rates in mucosal melanoma are lower than those observe
Externí odkaz:
https://doaj.org/article/24cb2e96d164402e9d316cff9ef36d9a
Autor:
Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth I. Buchbinder, Rizwan Haq, F. Stephen Hodi, Jonathan D. Schoenfeld, Patrick A. Ott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Abstract Background A male gender driven obesity paradox (improved survival for overweight/obese patients compared to normal weight) was recently shown in melanoma in the context of checkpoint inhibition (anti-PD-1/anti-CTLA4 monotherapy) in a pooled
Externí odkaz:
https://doaj.org/article/93d4682beb6d45b1ac4ee1d66abb75d5
Autor:
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable resp
Externí odkaz:
https://doaj.org/article/2501d6126ef24a80bcbed81058801563
Autor:
Peter G. Miller, Adam S. Sperling, Christopher J. Gibson, Olga Pozdnyakova, Waihay J. Wong, Michael P. Manos, Elizabeth I. Buchbinder, F. Stephen Hodi, Benjamin L. Ebert, Matthew S. Davids
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/1538e7473392467bb284a01f791481bb
Autor:
Nazli Dizman, Elizabeth I. Buchbinder
Publikováno v:
Cancers, Vol 13, Iss 24, p 6229 (2021)
In the past decade, the field of cancer immunotherapy has rapidly advanced, establishing a crucial role for immune checkpoint blockers in the treatment of a variety of cancer types. In parallel with these remarkable clinical developments, further eff
Externí odkaz:
https://doaj.org/article/7b8ce4f2767b451ab76f224a3515dd52
Autor:
Nageatte Ibrahim, Elizabeth I. Buchbinder, Scott R. Granter, Scott J. Rodig, Anita Giobbie‐Hurder, Carla Becerra, Argyro Tsiaras, Evisa Gjini, David E. Fisher, F. Stephen Hodi
Publikováno v:
Cancer Medicine, Vol 5, Iss 11, Pp 3041-3050 (2016)
Abstract Epigenetic alterations by histone/protein deacetylases (HDACs) are one of the many mechanisms that cancer cells use to alter gene expression and promote growth. HDAC inhibitors have proven to be effective in the treatment of specific maligna
Externí odkaz:
https://doaj.org/article/a5907865ba9c4716b2c5130ccca9596c
Autor:
Sandra Aung, Sigrun Hallmeyer, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Ryan J. Sullivan, Marc S. Ernstoff, Brendan D. Curti, Elizabeth I. Buchbinder, Rene Gonzalez, John M. Richart, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Girald P. Miletello, Joe Lutzky, Michael A. Morse
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However
Externí odkaz:
https://doaj.org/article/44e74afcb6e54cb58b9c7f23eb3b71b5
Autor:
Joseph M. Unger, Amy Darke, Megan Othus, Thach-Giao Truong, Nikhil Khushalani, Kari Kendra, Karl D. Lewis, Bryan Faller, Pauline Funchain, Elizabeth I. Buchbinder, Ahmad A. Tarhini, John M. Kirkwood, Elad Sharon, Vernon Sondak, Samantha R. Guild, Kenneth Grossmann, Antoni Ribas, Sapna P. Patel
Publikováno v:
JAMA oncology.
ImportanceA key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL).ObjectiveTo compare QOL in patients with resected melanoma at high risk for relaps